About Beikang Medical
Beikang Medical is a company based in Suzhou (China) founded in 2010. Beikang Medical has raised $36.52 million across 2 funding rounds from investors including Broad Vision Funds. The company has 497 employees as of December 31, 2024. Beikang Medical has completed 1 acquisition, including BMX Holdco. Beikang Medical operates in a competitive market with competitors including Natera, SYNLAB, Rejuvenate Bio, Novogene Corporation and Progenity, among others.
- Headquarter Suzhou, China
- Employees 497 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Suzhou Basecare Medical Corp. Ltd. Class H
-
Annual Revenue
$41.76 M (USD)41.12as on Dec 31, 2024
-
Net Profit
-$33.09 M (USD)-21.33as on Dec 31, 2024
-
EBITDA
-$33.66 M (USD)-3.78as on Dec 31, 2024
-
Total Equity Funding
$36.52 M (USD)
in 2 rounds
-
Latest Funding Round
$21.13 M (USD), Series C
May 15, 2020
- Investors
-
Employee Count
497
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Beikang Medical
Beikang Medical is a publicly listed company on the HKEX with ticker symbol 2170 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Beikang Medical
Beikang Medical has successfully raised a total of $36.52M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $21.13 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Beikang Medical
Beikang Medical has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Broad Vision Funds.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Consumer technology, healthcare, and sectors are targeted for venture investments.
|
Locked | Locked | Locked |
Investor details for Beikang Medical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Beikang Medical
Beikang Medical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include BMX Holdco.
Investment portfolio details for Beikang Medical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Multiple industries are operated by the diversified conglomerate.
|
Locked | Locked | 2022 | Locked |
Complete acquisition details for Beikang Medical
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Beikang Medical
Detailed financials for Beikang Medical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Beikang Medical Comparisons
Peer comparison for Beikang Medical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Beikang Medical
Beikang Medical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Natera, SYNLAB, Rejuvenate Bio, Novogene Corporation and Progenity, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of medical diagnosis and clinical laboratory analysis services
|
|
| Locked | Locked | Locked |
Gene-editing platform and anti-aging therapy for dogs are developed.
|
|
| Locked | Locked | Locked |
Genomic services and solutions with NGS expertise are provided.
|
|
| Locked | Locked | Locked |
Non-invasive prenatal genomic testing is provided for genetic disorders.
|
|
| Locked | Locked | Locked |
BGI is engaged in genomics and precision medicine solutions.
|
Detailed competitors of Beikang Medical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Beikang Medical
Complete news archive for Beikang Medical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Beikang Medical
Beikang Medical was founded in 2010 and raised its 1st funding round 7 years after it was founded.
Beikang Medical is headquartered in Suzhou, China. It is registered at Suzhou, Jiangsu, China.
Beikang Medical is a funded company, having raised a total of $36.52M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Beikang Medical is 497.
Annual revenue of Beikang Medical is $41.76M as on Dec 31, 2024.
Beikang Medical was founded in 2010 in Suzhou, China, within the genetic diagnostics sector. NGS-based solutions for neonatal and prenatal applications are developed and offered. Tests including pre-pregnancy, pre-implantation, non-invasive prenatal, and earlyneonatal genetic screening are provided under the Basecare brand. Operations are supported by Daan Gene Corp. of Sun Yat-Sen University, with the domain basecare.cn utilized.
Beikang Medical's top competitors include Natera, Novogene Corporation and BGI.
Yes, Beikang Medical is publicly traded on HKEX under the ticker symbol 2170.
Beikang Medical has made 1 acquisition, including BMX Holdco.
Beikang Medical has 1 investor. Key investors include Broad Vision Funds.
The ticker symbol of Beikang Medical is 2170 on HKEX.